文献速递腹部技术与安全CTMRPET

胃肠道与腹部肿瘤疗效评价标准:如何选择与如何测量

Response Evaluation Criteria in Gastrointestinal and Abdominal Cancers: Which to Use and How to Measure.
PubMed 文献 · Radiographics · 2024-01-01

本文综述胃肠道恶性肿瘤疗效评价的演进:从基于大小的评价扩展到包含肿瘤强化及PET、扩散加权成像等功能数据的评价。文中讨论免疫治疗等靶向治疗的特殊反应模式和药物毒性,指出部分胃肠道肿瘤需采用肿瘤特异性标准,并提示分子靶向治疗或富血供肿瘤局部治疗后解剖测量可能低估疗效,影像组学与多媒体增强报告有助于精准评估。

要点

  • 胃肠道肿瘤疗效评价已从单纯大小测量扩展到强化程度及PET、扩散加权成像等功能数据。
  • 免疫治疗等靶向治疗具有独特反应模式,已据此制定免疫治疗反应标准。
  • 富血供肿瘤(如肝细胞癌)经分子靶向或局部区域治疗后,肿瘤可呈囊性变、坏死、出血而体积无明显缩小,解剖测量可能低估疗效。

核心结论

  • 胃肠道肿瘤疗效评价需结合所用影像手段、抗癌治疗类型与肿瘤生物学;部分肿瘤需用特异性标准指导临床管理,如直肠癌观察等待、胰腺癌手术适宜性。
  • 分子靶向治疗或富血供恶性肿瘤局部区域治疗后,解剖测量可能低估治疗反应,反应肿瘤可表现为囊性变、坏死、出血而体积无明显缩小。
  • 影像组学等数据驱动图像分析已在多种胃肠道肿瘤中研究,用于识别更可能对治疗有反应或复发的肿瘤,以实现精准医学。

研究设计与样本

  • 本文为综述,检索范围与纳入文献原文未报告。

关键影像表现/征象

  • 反应肿瘤可呈现形态学改变,包括囊性变、坏死和出血,且常无显著体积缩小。

诊断标准与关键数值

  • 原文述及免疫治疗因独特影像反应模式和药物毒性而制定了免疫治疗反应标准,具体标准名称与数值原文未报告。
  • 部分胃肠道恶性肿瘤在评价疗效时需采用肿瘤特异性标准,具体标准原文未报告。

临床应用与阅片要点

  • 解读胃肠道肿瘤疗效评价影像时,需认识判读陷阱,以正确解释疗效评估影像并指导恰当的肿瘤治疗管理。
  • 多媒体增强放射学报告可自动嵌入反应类别、关键数据和代表性图像,便于沟通胃肠道肿瘤疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

As the management of gastrointestinal malignancy has evolved, tumor response assessment has expanded from size-based assessments to those that include tumor enhancement, in addition to functional data such as those derived from PET and diffusion-weighted imaging. Accurate interpretation of tumor response therefore requires knowledge of imaging modalities used in gastrointestinal malignancy, anticancer therapies, and tumor biology. Targeted therapies such as immunotherapy pose additional considerations due to unique imaging response patterns and drug toxicity; as a consequence, immunotherapy response criteria have been developed. Some gastrointestinal malignancies require assessment with tumor-specific criteria when assessing response, often to guide clinical management (such as watchful waiting in rectal cancer or suitability for surgery in pancreatic cancer). Moreover, anatomic measurements can underestimate therapeutic response when applied to molecular-targeted therapies or locoregional therapies in hypervascular malignancies such as hepatocellular carcinoma. In these cases, responding tumors may exhibit morphologic changes including cystic degeneration, necrosis, and hemorrhage, often without significant reduction in size. Awareness of pitfalls when interpreting gastrointestinal tumor response is required to correctly interpret response assessment imaging and guide appropriate oncologic management. Data-driven image analyses such as radiomics have been investigated in a variety of gastrointestinal tumors, such as identifying those more likely to respond to therapy or recur, with the aim of delivering precision medicine. Multimedia-enhanced radiology reports can facilitate communication of gastrointestinal tumor response by automatically embedding response categories, key data, and representative images. ©RSNA, 2024 Test Your Knowledge questions for this article are available in the supplemental material.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Castagnoli F, Mencel J, Ap Dafydd D, et al. Response Evaluation Criteria in Gastrointestinal and Abdominal Cancers: Which to Use and How to Measure. Radiographics. 2024. PMID: 38662587. doi:10.1148/rg.230047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。